BioCryst Pharmaceuticals, Inc. (BCRX) Earnings Call Transcript
May 6, 2026
Earnings Call Speaker Segments
Hello everyone, and thanks for joining BioCryst's conference call covering our Corporate Update and Financial Results for the first quarter of 2026. Here with me on the line are Charles Gayer, our President and CEO; Dr. Sandeep Menon, who serves as Chief R&D Officer; and Babar Ghias, our Chief Financial Officer. You can find a press release along with a slide deck covering today's announcements posted on the Investor Relations section of our website. During this call, we'll be making forward-looking statements, which include remarks about upcoming results, financial information that is unaudited and forward-looking, and the company's anticipated performance and/or achievements going forward. Known and unknown risks and uncertainties could affect these statements, and as a result our actual results, performance or achievements might differ materially from any future results or performance expressed or implied in this presentation. To learn more, including a detailed discussion of those risks, please see Slide 2 of the presentation. Also, non-GAAP financial measures are being discussed on today's conference call; a reconciliation of these non-GAAP financial measures against the most directly comparable GAAP financial measure can be found in the earnings press release available on our Investor Relations website. At this point, I'll hand the call over to Charlie.
Appreciate it, Nick. For BioCryst, 2026 has begun extremely well, defined by solid delivery across our commercial and development efforts, a seamless absorption of Astria Therapeutics, and careful stewardship of our balance sheet. Quarterly ORLADEYO net revenue came in at $148.3 million, exactly where we anticipated, while monthly prescriptions from new patients have run a touch above the 2025 averages. The pediatric indication launch is only getting underway, yet early indicators validate the demand for oral prophylaxis among children living with HAE. Scripts have come in for all 4 product strengths of ORLADEYO pellets, showing that kids who are even younger require prophylaxis; we remain dedicated to delivering oral prophy to the numerous children who depend on it. We also recently uncovered a manufacturing problem that will push back the initial product fulfillment, and our team is collaborating closely with our manufacturing partner to determine the root cause. We anticipate sharing additional details regarding product readiness later in this quarter, and we do not anticipate that this delay will impact our 2026 revenue guidance. We are eager to get ORLADEYO to the children who need it at the earliest opportunity. While the pediatric indication is thrilling, it does not pull our team away from generating new patient demand for ORLADEYO capsules; we are happy that new prescription demand among those ages 12 and up stays in line with our quarterly averages since launch, even with fresh competition. Physicians and patients keep putting their trust in ORLADEYO as a proven, effective HAE prophylaxis choice. Now to our pipeline development. Advancement of the pivotal ALPHA-ORBIT trial for navenibart has surpassed what we expected. Enrollment will wrap up by the close of next month and, at roughly 145 enrolled patients, ALPHA-ORBIT will stand as the biggest pivotal trial ever conducted for HAE prophylaxis. How quickly we enrolled speaks to our team's execution along with the appeal of navenibart's profile. Our Phase 1 study of BCX1775 in Netherton syndrome is likewise gaining momentum. Investigator enthusiasm has been robust. Dosing among patients has begun, and we remain on schedule to obtain proof-of-concept data before this year ends in this high-need rare disease. I am delighted that Dr. Sandeep Menon came aboard as Chief R&D Officer last month; our pipeline is advancing nicely, and bringing in Sandeep strengthens us. He brings a history of disciplined, successful drug development, and he shares our vision of creating substantial value by serving rare disease patients. I'll hand things to Sandeep so he can introduce himself.
Thanks, Charlie. It’s a thrill for me to come aboard BioCryst at this pivotal moment in the company’s development. We hold a distinctive position of strength, particularly given how well ORLADEYO has performed. What attracted me to BioCryst wasn’t merely commercial excellence, but also the dedication to rigorous science aimed at bettering patients’ lives. I believe there’s an enormous chance to extend the momentum ORLADEYO has created as we steer the next set of programs through the clinic. Enrollment for Navenibart, our injectable plasma kallikrein inhibitor intended for HAE prophylaxis, will wrap up in the ongoing pivotal Phase 3 ALPHA-ORBIT study by the close of June this year; that keeps us positioned to make a regulatory submission in the U.S. by the close of next year. Thus far, Navenibart has produced persuasive clinical evidence. In the long-term open-label ALPHA-SOLAR study, it recently showed mean attack reductions of 92% and 90% for the 3-month and 6-month dosing regimens, respectively. We now have a strong chance to deliver a potentially best-in-class injectable to HAE patients that would complement our best-in-class oral ORLADEYO. Turning to our following program, BCX17725, a KLK5 inhibitor that could be first-in-class for Netherton syndrome, an extremely severe skin condition with no targeted or approved therapies available to patients. I’m glad to report that dosing has begun in patients in Part 4 of the ongoing Phase 1 study. Part 4 will enroll as many as 12 patients with 3 months of dosing, and we anticipate reporting these data by the close of this year. In addition to BCX17725, we’ll stay disciplined in what we go after, whether internally or externally, concentrating on rare diseases, which align with our strengths. I’m eager for the chance to help shape the next chapter of BioCryst’s growth. We possess a demonstrated track record in HAE, promising assets moving forward in the clinic and now a clear strategy for further broadening our presence in rare disease. I’m looking forward to updating you on our continued progress throughout the year. I’ll now hand things over to my colleague, Babar Ghias.
Thank you, Sandeep. During my comments today, I'll be discussing non-GAAP numbers, and those are adjusted to account for revenues and expenses tied to our European ORLADEYO business, stock-based comp, plus costs stemming from the Astria acquisition. For accounting purposes, that acquisition was classified as an asset acquisition. Consequently, we booked an in-process R&D charge of $698 million during Q1, along with certain other charges specific to the transaction. I'd urge you to look over our press release, which contains further detail about these adjustments. Our view is that non-GAAP numbers offer a clearer picture of how strong our business is on a forward-looking basis, and we'd encourage you to center your analysis on these metrics. That said, 2026 has gotten off to a strong start, with first quarter results showing continued momentum for ORLADEYO, which further demonstrates the product's durability in an HAE market where patient options keep increasing. Not only did we deliver strong top line growth during the quarter, we also posted a strong non-GAAP operating profit. The consistency of our profitability trend pleases us, and it adds to our strong balance sheet position. On top of that, we've been very pleased with how the overall integration of Astria Therapeutics into the BioCryst family has gone. That process has been running ahead of what we expected. It shows that our team can, in the future, not only pull off transformational BD but also integrate seamlessly. To shed more light on our financial figures, non-GAAP total revenue for Q1 2026 rose approximately 17% year-on-year. Because other revenues include contribution from RAPIVAB and licensing revenues, I'd point you toward ORLADEYO revenues of $148 million, up 21% year-on-year, excluding the European divestiture impact. New prescription demand is strong, and growth in prescribers continues even in the sixth year of launch. We remain very excited about future growth prospects for ORLADEYO as more prescribers gain experience with the pediatric formulation and the commercial team keeps reinforcing and expanding the value proposition of ORLADEYO; in Q1, our non-GAAP operating profit reached $54 million, up 25% year-on-year, which further demonstrates our ability to convert strong top line growth into bottom line growth. R&D costs rose in Q1 2026 versus the prior year, as you'd expect, since we are now consolidating costs related to navenibart. To refresh from the last call, we anticipate that 2026 R&D costs will increase over 2025 as we complete the ongoing Phase 3 trial and BLA-enabling CMC activities for navenibart. With Sandeep added to our team, we will keep refining a focused and disciplined R&D strategy to enhance our portfolio. Toward that end, we will keep evaluating internal programs that don't make viable business sense. And as part of that evaluation during Q1, we decided to discontinue the development of avoralstat in DME. Our sales and marketing expenses for the quarter were $37 million on a non-GAAP basis, down slightly from Q1 2025. We're really happy that our sales and marketing organization has reached a stable state. And although variable expenses might rise a bit more, the team we have right now is appropriately sized to back ORLADEYO's ongoing growth. We expect that sales and marketing spending in support of our HAE business — ORLADEYO and navenibart, should it be approved — taken together will remain quite steady and is set up to produce meaningful returns. On a non-GAAP basis, our G&A expense came in slightly higher, up $1.8 million versus Q1 2025. The main reason for that rise was added overhead tied to completing the Astria deal; we'll keep watching our G&A throughout 2026 and look for more places to gain efficiencies. Thanks to our solid operational performance, we closed the first quarter with considerable liquidity — roughly $261 million across cash and investments — even after covering a portion of the Astria purchase price from our own balance sheet. In the quarter, we also completed a $400 million senior credit facility to cover the rest of the cash component of the Astria acquisition, plus about 37 million BioCryst shares that were issued to Astria's shareholders. Our cost of capital came down relative to last year thanks to our strong financial standing, and you'll see that benefit show up year over year in our interest expense. Earlier this week, we wrapped up the license agreement with Neopharmed Gentili covering commercialization of navenibart in Europe. We're glad to be working with NG on this deal. It's a team sharing one vision for helping people who live with HAE, and a commercial group that was carefully built over many years before moving to NG through our European divestiture last year. Under this deal, we get $70 million in upfront cash and as much as $225 million in future regulatory and sales milestones, plus tiered royalties on net sales that run from 18% to 30% overall; this will meaningfully reinforce our balance sheet in the near to medium term, and of course the downstream economics will look attractive within our overall financial profile. On a pro forma basis, counting the net proceeds from the license agreement, our liquidity position totals $331 million as of March 31, 2026. That appealing position lets us consider a broad range of capital allocation approaches to maximize shareholder value. Turning quickly to guidance. As Charlie noted, we're keeping our expectation for full year 2026 ORLADEYO revenues at between $625 million and $645 million; we expect full year 2026 non-GAAP OpEx of between $450 million and $470 million; we keep executing well; and as the year moves along, we'll update the Street on any changes. To wrap up, we've come into 2026 with strong momentum and are glad to see solid trends early in Q2. We aim to continue pushing revenue and earnings higher, moving our pipeline forward via internal innovation as well as carefully chosen, disciplined business development, so we can speed up the difference we make for patients with rare diseases; it's a pleasure to bring all of you these encouraging updates on our operations today. And operator, we're prepared to take questions now.
This is Abdullah, filling in for Jess. We've got just a couple of questions. First, what are your expectations regarding the pivotal readout for deucrictibant XR? And what kind of profile are you anticipating? Then, what are the most recent trends — what are your latest trends concerning the paid rate within each payer segment?
Sure. Regarding deucrictibant, as we've mentioned previously, we put in a great deal of effort attempting to forecast what lies ahead. Our forecasting models have demonstrated they are extremely accurate from launch through today, and they genuinely anticipated ORLADEYO's growth. We consistently assign our upcoming rivals their strongest possible profile. Therefore, our assumption is that deucrictibant will demonstrate quite strong efficacy at the time they report in Q3. That is incorporated into our forward-looking forecast; and we continue to hold the belief that ORLADEYO remains on a trajectory and will hit $1 billion in peak sales; and concerning the trends in the paid rate, we are still — during this year, we remain in the blizzard season, when we work through all of the reauthorization. Each year, it shifts somewhat further out as patients undergo this process. So that process is still ongoing for us. We will say more once Q2 wraps up. However, we are achieving genuinely strong success in converting patients from long-term free product over to paid product. So things are moving along the way we anticipated.
This is Jeremiah, filling in for Tazeen. We might have a few questions. First, regarding the navenibart out-licensing deal, could you help us get a sense of how much of that $275 million milestone pool is tied to regulatory versus commercial thresholds? And then, where do you expect that royalty rate to settle at scale? Then maybe a pipeline question, especially given the prioritization of avoralstat. We're just wondering — we haven't heard many updates about the complement pipeline in some time. What are the next key decision points for bringing those programs forward?
Babar, do you want to take the royalty question? I'll cover the pipeline.
Yeah. So I'd say right now, we aren't really laying out the specific milestones, and honestly we're pretty thrilled that the upfront component represents a meaningful potential upside for an asset at this point, and it's naturally fairly consistent with certain licensing deals we've done previously at a similar stage. As you can tell, we have a lot of confidence in that solid royalty rate, since, like I said, this is a team we built and refined ourselves across a number of years. So we're quite sure the team is going to perform really well, and we'll capture the fullest advantage from that royalty rate. That said, you can picture what a standard arrangement looks like on the backend in terms of those elements, though it's something we're genuinely confident we'll achieve as time goes on.
Now regarding our pipeline, first off, our current focus is on the two programs we have in clinical development. That means navenibart in late stage, and then we're quite enthusiastic about what 17725 could offer, considering the need within the Netherton's population. With Sandeep now with us, we'll be providing future updates on our pipeline as well as our rare disease strategy, and we're eager to do so as soon as possible.
Let's go back to ORLADEYO for a moment. Charlie, I don't know whether you're able to provide any comments regarding how some rival launches are playing out at present. DAWNZERA comes to mind, but what sort of effect are you observing when it comes to keeping patients on ORLADEYO? Has your approach to talking with doctors shifted in any way because of this? Then, one more question related to the manufacturing problem. I believe I didn't catch it, but are there any consequences? Or might you give a bit more detail about what it means for the pediatric rollout?
Of course. Laura, when it comes to those rival launches, the situation matches our expectations, and once again this ties back to the way we build our forecasts. As you're aware, the products launched recently are injectables. Consequently, in our view they're mostly going head-to-head with TAKHZYRO, the current leader in the market. Because of that, ORLADEYO isn't being hurt. Both Babar and I have said our demand has never been stronger, and we're genuinely happy — not taken aback, but genuinely happy — to witness that. That's the reason we keep holding that confidence regarding ORLADEYO's future growth and its path toward $1 billion in peak sales. Regarding retention rates, which you brought up, those too match what we'd anticipated previously. Among patients beginning ORLADEYO, 60% remain on it through a year, and after that it becomes very slow or very sticky, with very strong retention beyond a year; on the pediatric manufacturing side, as we've stated, our guidance stays the same. We expect to share more details about the issue and its timing, ideally later this quarter. Even so, our guidance stays the same since early demand has been very strong; and you might remember from earlier calls that in our forecast for this year, we took a fairly conservative view of the pediatric opportunity, given that we didn't know how fast it would take off. So our long-term view is very bullish, and this year we remain on track.
I've got a couple of questions. First, regarding navenibart Phase 3 — from what you're saying, enrollment seems to have gone quite smoothly. So could you share any insights you've gained, particularly around how enrollment was conducted, what the demand looks like for long-acting injectables, which patient types might use this commercially, and how big that opportunity could be? Then secondly, to follow up on the manufacturing problem: can you tell us what it would take to fix it? Would an FDA reinspection be necessary? Does this facility have anything to do with ORLADEYO for adults or with navenibart? And if this gets sorted out sooner than anticipated, could that mean upside to your guidance, since launch demand already looks strong and I realize pediatric revenue was barely factored into your guidance?
Sure, thanks Brian. On navenibart first — we're genuinely thrilled with how quickly enrollment is moving. Like I mentioned earlier, I believe it shows how much both patients and physicians want an every 3- or 6-month dosing option. That's exactly why we pursued acquiring this product initially, because we observed it and heard it directly from customers. Reaching 3- and 6-month dosing is truly significant and transformative, so we see potential to move a large number of patients onto it. As we've explained previously, this market has two segments. One is patients who prefer oral therapy and do well with it. The other is patients already using injectables and feeling very at ease with them. The navenibart profile is something both physicians and patients can readily grasp, and I think that's once again evident in the trial enrollment. So we're eager about that upcoming launch. Now regarding the manufacturing problem with ORLADEYO pellets — to start, this involves a different plant and a different manufacturer than capsules do. So capsules are entirely unrelated. It's not an FDA matter whatsoever, and it's not a safety matter. It's simply a batch issue with specifications. We're investigating to find the root cause so we can produce consistent batches moving forward. We'll share an update on timing once we have one, but we don't anticipate this being a long-term issue. As for pediatric indication demand, it's been very strong so far. So if we resolve this and get product out in the fairly near future, we're right on track for this year and definitely very much on track for our long-term predictions.
I was curious whether you could lay out what you anticipate from the Phase 3 navenibart readout. Clearly, the majority of Phase 2 trials, this HAE one included, run smaller than a Phase 3 would, yet the drop in attack rate during that Phase 2 was quite striking; so do you anticipate something like a reduction in attack rate above 90%? Do you figure on seeing that in the arm dosed every 3 months as well as the one dosed every 6 months? And does that explain the rather bold guidance, since $1.8 billion in 2033 sort of suggests a launch even stronger than ORLADEYO? So I was hoping you might lay out what you anticipate from the data.
We anticipate genuinely strong results, and whether that's 90%, slightly above 90%, slightly below, I don't believe that matters all that much. What counts is the attack rate patients actually reach. And in the open-label study, as you've observed, patients on both doses are reaching a mean attack rate of merely 0.16 per month. That works out to fewer than 2 attacks each year; and those attacks are typically milder than other attacks. So functionally, that means patients are attack-free. And achieving that with dosing every 3 or 6 months, we do anticipate comparable efficacy across the 2, since keep in mind the 6-month dosing uses double the dose given at 3 months. And so that Phase 2 ALPHA-SOLAR data matters a great deal, truly giving us confidence going forward.
Hello, Sandeep. To start, when I think about ORLADEYO, I saw that you mentioned ongoing expansion in the number of prescribers. I'm just wondering if you could say more about that. That's my first question. Then a quick follow-up regarding fulfillment of the pediatric product. It sounds like you need 1 quarter or 2 to gather additional information? Or is it to fix the fulfillment problem? So just help us understand whether the base case assumption for the possible delay is likely inside this year; that's number two. Third, since you've started giving the drug to more patients, could you tell us more about what you're learning concerning the patient population, how aware people are of the diagnosis, how big the market might be, and also remind us about your go or no-go call on efficacy.
Sure. Thanks, Stacy. I'll try to cover each of those points. On the topic of prescriber growth, you've heard from us before that during 2025, we were adding about 60 new prescribers per month, give or take. Q1 has stayed in that same neighborhood. So, as Babar mentioned, being in year 6 and still bringing on prescribers, still seeing prescriptions come in at the same pace, truly speaks to the profile of this product and the way our teams brought it to market. On the peds pellet timeline—like I mentioned, we should have a clearer picture during this quarter. We're hoping to wrap it up fairly fast. That said, the root cause remains unknown; we still haven't pinned down all of what's driving it. So it's going to require some time. Even so, judging by where things stand today, we believe we'll stay on schedule for the year. Turning to Netherton patients: we've put in effort on the epidemiology side of this condition, since that matters a great deal. This is a highly serious disease—we've spent time with patients and understand the burden they carry. The crucial question, though, comes down to market size and what the total opportunity looks like. We feel quite sure that, right now, more than 3,000 patients exist in the U.S. market. Those individuals have to receive the right diagnosis. They have to be found. Even so, when a therapy is available commercially, that always acts as a trigger for locating patients in rare disease. Therefore, regarding efficacy, perfection isn't required from any medicine in this area. What we hope to observe is improvement in patients across the general — the general instruments used to assess Netherton syndrome; that means ichthyosis scales as rated by physicians and by patients, and we'll examine both. Our focus will be on whether the drug still reaches the epidermis as it did with healthy volunteers. So a variety of factors will guide how we shape a pivotal program, which we're hoping to kick off next year.
Nice work on the advances. Perhaps a brief additional question regarding Netherton. Could you elaborate on the volume of data we ought to anticipate by the close of the year for that data update?
Sure. Maury, we are aiming for as many as 12 patients. That is our target; and since this is a rare disease, we intend to put out everything we gather at once. It isn't a very large patient count, yet we believe it will provide the information required to determine whether we have a drug here. So the package will be derived from that in addition to the 1 to 3 patients coming from Part 3 of the study, along with the healthy volunteer data; thus, as information arrives, we will determine what the package looks like at year's end, though it will rest on those approximately 12 patients.
Understood. All right. So to probe a little deeper into the prophylactic rivalry, are you picking up on a growing number of patients who are thinking about making a change or actually leaving ORLADEYO? And even if no effect is showing up yet, are you encountering added strain or obstacles when it comes to bringing in new patients or winning switches away from TAKHZYRO? It strikes me that ORLADEYO is holding up well despite these new entrants. Is there anything you're handling in a different way?
Right. Honestly, our approach hasn't changed at all. We're not — there's no need for us to grow our sales force. There's no need to alter who our customers are. We already reach out to the roster of HAE prescribers and keep widening that roster, as we've discussed. What we observe is that the bulk of switching, the bulk of the market effect, lands on TAKHZYRO rather than ORLADEYO. Naturally, patients do leave ORLADEYO frequently. 60% of them reach a year, 40% do not, and they move to other products. And what we're noticing more often is that those patients, at the point they do switch, tend to move to one of the new products, which is quite logical. But the overall effect on ORLADEYO has been extremely small.
Catherine here, filling in for John. I appreciate the details regarding the ORLADEYO launch. Could you give us a bit more insight into sales outside the U.S. that go beyond Europe — what you're observing in those markets, any thoughts on expanding further — and then share your perspective on the same topic for navenibart?
Absolutely. Thank you, Catherine. Once we sold the European business, Europe had represented the bulk of our sales outside the U.S.; so revenue from outside the U.S. remains a meaningful part of reaching our peak, but at present — the overwhelming share, in fact greater than 90% of our revenue, is generated in the U.S., and we anticipate that will continue even as the brand climbs toward $1 billion. That said, we remain dedicated. Our goal is to bring our medicines to patients worldwide, since HAE is a disease that affects the globe, and there are people who require treatment. However, when it comes to revenue, the U.S. will account for the vast majority; and I apologize, regarding the question on — you had asked about navenibart.
For navenibart, do you figure the pattern will end up being similar, with most of the non-U.S. business coming from Europe?
Our expectation is that it will be more or less identical to what Babar outlined. The folks we work with at Neopharmed Gentili feel just as enthusiastic regarding this therapy, and with ORLADEYO plus navenibart both sitting in the portfolio, each of these two products has a significant role to play across every one of the various markets. That prospect has us energized.
This is Yesha calling in for Gavin. We wanted to ask, on the pediatric pellet front, can you actively push through payer access and reimbursement at the same time as you're sorting out the manufacturing? Also curious how fast you might turn that demand into paid drug once it's sorted.
Yes. Appreciate the question. Definitely, that work is already underway. And we'll keep at it. The ORLADEYO pellets fit directly into the contracts we already have for ORLADEYO capsules. So it isn't really a distinct market access effort. And so our patient services team will assist patients and health care providers in navigating that process. And that might get patients transitioning sooner to paid therapy once we do have product supply.
Thanks. Once more, as Babar, Sandeep, and I have laid out during this call, BioCryst has gotten off to a really strong beginning in 2026. I'm quite pleased with the team that we have assembled here, and with how we're carrying out our commercial and development programs. And my belief is that the finest days for BioCryst are still ahead. I appreciate your interest, and I hope everyone has a great day.
That wraps up our call. We appreciate everyone joining us for today's presentation, and at this point you're free to hang up.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete BioCryst Pharmaceuticals, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to BioCryst Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.